Navigation Links
Gene therapy for human skin disease produces long-term benefits
Date:12/26/2013

Stem cell-based gene therapy holds promise for the treatment of devastating genetic skin diseases, but the long-term clinical outcomes of this approach have been unclear. In a study online December 26th in the ISSCR's journal Stem Cell Reports, published by Cell Press, researchers evaluated a patient with a genetic skin disorder known as epidermolysis bullosa (EB) nearly seven years after he had undergone a gene therapy procedure as part of a clinical trial. The study revealed that a small number of skin stem cells transplanted into the patient's legs were sufficient to restore normal skin function, without causing any adverse side effects.

"These findings pave the way for the future safe use of epidermal stem cells for combined cell and gene therapy of epidermolysis bullosa and other genetic skin diseases," says senior study author Michele De Luca of the University of Modena and Reggio Emilia.

EB is a painful condition that causes the skin to be very fragile and to blister easily, and it can also cause life-threatening infections. Because there is no cure for the disease, current treatment strategies focus on relieving symptoms. To evaluate stem cell-based gene therapy as a potential treatment, De Luca and his colleagues previously launched a phase I/II clinical trial at the University of Modena and recruited an EB patient named Claudio. The researchers took skin stem cells from Claudio's palm, corrected the genetic defect in these cells, and then transplanted them into Claudio's upper legs.

In the new study, De Luca and his team found that this treatment resulted in long-term restoration of normal skin function. Nearly seven years later, Claudio's upper legs looked normal and did not show signs of blisters, and there was no evidence of tumor development. Remarkably, a small number of transplanted stem cells was sufficient for long-lasting skin regeneration.

Even though Claudio's skin had undergone about 80 cycles
'/>"/>

Contact: Mary Beth O'Leary
moleary@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Page: 1 2

Related biology news :

1. Combination of cell transplantation and gene therapy for Alzheimers disease
2. Blue light phototherapy kills antibiotic-resistant bacteria, according to new studies
3. National award honors CHOP scientist for career work in gene therapy for hemophilia
4. Deep sequencing of breast cancer tumors to predict clinical outcomes after single dose of therapy
5. New gene therapy proves promising as hemophilia treatment
6. How can we improve the efficacy of antipsychotics in the era of personalized pharmacotherapy?
7. T cell immunotherapy: Promising results in children and adults with leukemia
8. International gene therapy trial for bubble boy disease shows promising early results
9. Penn Medicine team reports on study of first 59 leukemia patients who received cell therapy
10. Top 12 Pioneer Awards for seminal work in gene and cell therapy selected by blue ribbon panel
11. Hormone therapy could enhance the therapeutic effect of head and facial bone grafts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2
... Oct. 27, 2009 UT Southwestern Medical Center patient ... receive the newest generation of a mechanical device designed to ... awaits a heart transplant. Called a left-ventricular assist device ... pump blood throughout the body. For Mr. LeBlanc, it will ...
... 45 percent of blood, normally take the shape of circular ... sometimes deform into an asymmetrical slipper shape. A team ... might be responsible for this deformation, as well as how ... help understand the mechanisms involved in arterial disease and other ...
... nest? Early in development infants of many species experience ... presence of their mother to start exploring the wider ... the brain during that turning point. Based on ... strength of attachments in many speciesincluding the conundrum of ...
Cached Biology News:UT Southwestern patient first in North Texas to receive newest-generation heart failure device 2UT Southwestern patient first in North Texas to receive newest-generation heart failure device 3Changes in brain chemicals mark shifts in infant learning 2Changes in brain chemicals mark shifts in infant learning 3
(Date:3/3/2015)... and TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... quarter and seventh-month period ended December 31, 2014. ... fiscal year end from May 31 to December 31. ... are reporting today are for the quarter and the ...
(Date:3/3/2015)... , March 3, 2015 NASA astronaut ... launch this month to spend a year living and working ... satellite interviews from 5:30 to 7 a.m. EDT Monday, March ... as he completes the final weeks of his ... a video on NASA Television highlighting his mission training and ...
(Date:3/3/2015)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced several new ... in North America , the Middle ... "Bidding activity in 2015 continues to be robust" said Derek ... for bidding in 2014, we are pleased to see the bidding ... organization,s renewed focus on select market segments where we can add ...
(Date:3/3/2015)... , March 3, 2015  Neurocrine Biosciences, Inc. ... Kevin Gorman , President and Chief Executive Officer of ... Healthcare Conference in Miami.   The live ... ET (7:15am PT).  The presentation will be webcast and ... http://www.neurocrine.com .   Listeners are encouraged to ...
Breaking Biology Technology:Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... Bulletin Board:,NTRZ), a world leader in stabilized rice ... it has appointed Olga Hernandez-Longan [45],to the position ... with,his previously announced intentions, has retired as CFO, ... capacity., Ms. Hernandez-Longan has over 20 years ...
... higher revenue due to Roche milestone -, BRISBANE, Calif., ... results from operations for the third,quarter and nine months ended ... quarter of 2008 of $12.5 million, or $0.32 per share,compared ... share, in the third,quarter of 2007., Dan Welch, Chairman, ...
... Nov. 6 ViroPharma Incorporated,(Nasdaq: VPHM ) ... officer of ViroPharma, will present at the Rodman ... ET on Wednesday, November,12, 2008. The conference is ... ViroPharma also announced that Colin Broom, vice ...
Cached Biology Technology:NutraCea Appoints New Chief Financial Officer 2InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 2InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 3InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 4InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 5InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 6InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 7InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 8InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 9ViroPharma to Present at Three November Healthcare Conferences 2
MAb to Mouse MHC Class I H-2Kd...
... Gel-Digesting Preparation contains a unique β-agarose digesting ... recovery of intact DNA and RNA from ... electrophoresis in TAE, TBE, MOPS, or phosphate ... in the TAE, TBE, MOPS, and phosphate ...
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
... Perhaps sheer in-house demand is causing shortages ... your precious antibody. This can cause unwanted ... • Receive royalties for your hard work ... let us build it up and market ...
Biology Products: